Stryker Corp.

SYK-N

Get Alerts91 watching

NYSE:SYK

207.03
8.95 (4.52%)
Stryker Corporation is a Fortune 500 medical technologies firm based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and ...
More at Wikipedia
SYK Fundamental Data  by TradingView
SYK Chart  by TradingView
Technical Analysis for SYK  by TradingView

Analysis and Opinions about SYK-N

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
Stryker Corp. (SYK-N)
December 18, 2019

SYK vs. JNJ SYK makes medical products while JNJ also produces that plus pharma and personal care products, but are fighting talcum powder lawsuits that will persist. Despite this, he much prefers JNJ due to better diversification and valuation. But wait for a better entry point.

Show full opinionHide full opinion
Stryker Corp. (SYK-N)
December 18, 2019

SYK vs. JNJ SYK makes medical products while JNJ also produces that plus pharma and personal care products, but are fighting talcum powder lawsuits that will persist. Despite this, he much prefers JNJ due to better diversification and valuation. But wait for a better entry point.

biotechnology/pharmaceutical
0 Comments
Lorne Steinberg

☆ Unlock Ratings

Price
$208.520
Owned
Unknown
BUY
BUY
Stryker Corp. (SYK-N)
November 27, 2019
Diversified in orthopedics and medical instruments. Zimmer falling on hard times has been to its benefit. Not that expensive, around 20x earnings. Likes it.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
November 27, 2019
Diversified in orthopedics and medical instruments. Zimmer falling on hard times has been to its benefit. Not that expensive, around 20x earnings. Likes it.
biotechnology/pharmaceutical
0 Comments
Gordon Reid

☆ Unlock Ratings

Price
$204.940
Owned
No
PAST TOP PICK
PAST TOP PICK
Stryker Corp. (SYK-N)
November 7, 2019
(A Top Pick Nov 20/18, Up 22%) Demographically, in a great spot. Recent acquisition will expand their market. Developing robotics. Positive long-term.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
November 7, 2019
(A Top Pick Nov 20/18, Up 22%) Demographically, in a great spot. Recent acquisition will expand their market. Developing robotics. Positive long-term.
biotechnology/pharmaceutical
0 Comments
Zachary Curry

☆ Unlock Ratings

Price
$200.780
Owned
Yes
BUY
BUY
Stryker Corp. (SYK-N)
October 28, 2019
They don't have the patent cliffs that the drugs are going to come off, and they will continue to innovate. Aging demographics will help demand. He's happy to hold this.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
October 28, 2019
They don't have the patent cliffs that the drugs are going to come off, and they will continue to innovate. Aging demographics will help demand. He's happy to hold this.
biotechnology/pharmaceutical
0 Comments
Brett Girard, CPA, CA, CFA

☆ Unlock Ratings

Price
$213.720
Owned
Yes
BUY
BUY
Stryker Corp. (SYK-N)
July 17, 2019
One of his favourite medtech names. They lead in robotic surgery. Great organic growth. They're setting up for a great quarter.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
July 17, 2019
One of his favourite medtech names. They lead in robotic surgery. Great organic growth. They're setting up for a great quarter.
biotechnology/pharmaceutical
0 Comments
Paul MacDonald

☆ Unlock Ratings

Price
$207.950
Owned
Yes
BUY
BUY
Stryker Corp. (SYK-N)
June 27, 2019
The medical device sector has been a leading group for the last three years and he has been a big proponent. They are interesting because it is secular growth. Demographics support what these companies are doing. They are very defensible because they are not tied to the economic cycle. So long as growth performs well, he likes this group. He owns it through the medical devices ETF.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
June 27, 2019
The medical device sector has been a leading group for the last three years and he has been a big proponent. They are interesting because it is secular growth. Demographics support what these companies are doing. They are very defensible because they are not tied to the economic cycle. So long as growth performs well, he likes this group. He owns it through the medical devices ETF.
biotechnology/pharmaceutical
0 Comments
David Burrows

☆ Unlock Ratings

Price
$202.540
Owned
Yes
PAST TOP PICK
PAST TOP PICK
Stryker Corp. (SYK-N)
June 21, 2019
(A Top Pick Aug 17/18, Up 20%) Hips and knees. Robots doing knee surgery. 3D replacements for hips. Continues to chug along. Growing revenue 6-7%.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
June 21, 2019
(A Top Pick Aug 17/18, Up 20%) Hips and knees. Robots doing knee surgery. 3D replacements for hips. Continues to chug along. Growing revenue 6-7%.
biotechnology/pharmaceutical
0 Comments
David Driscoll

☆ Unlock Ratings

Price
$202.720
Owned
Yes
TOP PICK
TOP PICK
Stryker Corp. (SYK-N)
June 4, 2019

Medical devices in a great demographic growth area. They are developing robotics to assist in surgery. Think of it as a med-tech company. Yield 1.1% (Analysts’ price target is $201.12)

Show full opinionHide full opinion
Stryker Corp. (SYK-N)
June 4, 2019

Medical devices in a great demographic growth area. They are developing robotics to assist in surgery. Think of it as a med-tech company. Yield 1.1% (Analysts’ price target is $201.12)

biotechnology/pharmaceutical
0 Comments
Zachary Curry

☆ Unlock Ratings

Price
$186.450
Owned
Yes
TOP PICK
TOP PICK
Stryker Corp. (SYK-N)
May 21, 2019
Medical devices company. Great company. Will continue to grow with the aging population. 73% of the business in the U.S., 23% in Europe and the rest emerging markets. Can grow their business internationally. Very little debt. Great story, great growth and operating margins. (Analysts’ price target is $201.12)
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
May 21, 2019
Medical devices company. Great company. Will continue to grow with the aging population. 73% of the business in the U.S., 23% in Europe and the rest emerging markets. Can grow their business internationally. Very little debt. Great story, great growth and operating margins. (Analysts’ price target is $201.12)
biotechnology/pharmaceutical
0 Comments
Paul Harris, CFA

☆ Unlock Ratings

Price
$185.450
Owned
Yes
PAST TOP PICK
PAST TOP PICK
Stryker Corp. (SYK-N)
May 3, 2019
(A Top Pick Mar 21/18, Up 17%) Fantastic company in diverse medical devices. Leader in hip and knee replacements. Latest quarter was fantastic.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
May 3, 2019
(A Top Pick Mar 21/18, Up 17%) Fantastic company in diverse medical devices. Leader in hip and knee replacements. Latest quarter was fantastic.
biotechnology/pharmaceutical
0 Comments
Paul MacDonald

☆ Unlock Ratings

Price
$190.710
Owned
Yes
BUY
BUY
Stryker Corp. (SYK-N)
April 22, 2019
Great company, trading cheap in the low-20's. It will do well as its competitors stumble.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
April 22, 2019
Great company, trading cheap in the low-20's. It will do well as its competitors stumble.
biotechnology/pharmaceutical
0 Comments
Gordon Reid

☆ Unlock Ratings

Price
$182.160
Owned
Unknown
BUY
BUY
Stryker Corp. (SYK-N)
April 9, 2019
A great company that makes medical devices and does hip replacements. A surgeon that uses their equipment won't suddenly switch to another brand; the doctor will stay with Stryker. A problem is that sometimes the FDA approves medical devices too quickly--though that isn't a problem with Stryker. This is a good long-term hold.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
April 9, 2019
A great company that makes medical devices and does hip replacements. A surgeon that uses their equipment won't suddenly switch to another brand; the doctor will stay with Stryker. A problem is that sometimes the FDA approves medical devices too quickly--though that isn't a problem with Stryker. This is a good long-term hold.
biotechnology/pharmaceutical
0 Comments
Paul Harris, CFA

☆ Unlock Ratings

Price
$195.970
Owned
No
BUY WEAKNESS
BUY WEAKNESS
Stryker Corp. (SYK-N)
March 21, 2019
The valuation is about a 10-15% premium to the market. It has predictable growth and has done quite well. They have distinguished themselves in the way they can execute. He prefers this one to others in the space. He would be interested at a lower price.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
March 21, 2019
The valuation is about a 10-15% premium to the market. It has predictable growth and has done quite well. They have distinguished themselves in the way they can execute. He prefers this one to others in the space. He would be interested at a lower price.
biotechnology/pharmaceutical
0 Comments
Gordon Reid

☆ Unlock Ratings

Price
$198.000
Owned
No
HOLD
HOLD
Stryker Corp. (SYK-N)
February 15, 2019
Earnings in last quarter had 6-7% organic growth, 2-3 times better than the competition. Not cheap at 23x earnings. Has differentiated itself from the others in its industry. As long as dividends are growing at a hefty rate, no reason to sell.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
February 15, 2019
Earnings in last quarter had 6-7% organic growth, 2-3 times better than the competition. Not cheap at 23x earnings. Has differentiated itself from the others in its industry. As long as dividends are growing at a hefty rate, no reason to sell.
biotechnology/pharmaceutical
0 Comments
David Driscoll

☆ Unlock Ratings

Price
$187.400
Owned
Unknown
BUY
BUY
Stryker Corp. (SYK-N)
February 13, 2019
A great medical tech company making equipment for knee replacements and spines. SYK spends a lot of time training doctors to use their equipment, which is not interchangeable with other manufacturers, so those doctors will continue to use SKY equipment. Demographics as society ages help SYK. Well-run, and it hit new highs today. This is a great story. Will do well long-term.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
February 13, 2019
A great medical tech company making equipment for knee replacements and spines. SYK spends a lot of time training doctors to use their equipment, which is not interchangeable with other manufacturers, so those doctors will continue to use SKY equipment. Demographics as society ages help SYK. Well-run, and it hit new highs today. This is a great story. Will do well long-term.
biotechnology/pharmaceutical
0 Comments
Paul Harris, CFA

☆ Unlock Ratings

Price
$185.630
Owned
Unknown
Showing 16 to 30 of 89 entries
Previous
Next Page
© Stockchase Inc.